Digital Pathology Market Definition And Segments

Digital pathology is the process of the use of digital imaging for pathology procedures. Digital pathology equipment converts glass slides into high-resolution digital images by utilizing slide scanner hardware, software, and services. These images can be viewed, managed, and analyzed on a computer or mobile screen. The main types of products in digital pathology include scanners, software, communication systems, and storage systems. The scanner uses microscopic array technology to produce a three-dimensional digital representation of a pathology slide for viewing and automated image analysis. The software transfers the data into a digital medium for image review and analysis and tissue image analysis. Communication systems are used to communicate between separate whole slide acquisition, storage, and viewing components and also to remote colleagues using real-time telepathology. Storage systems consist of the digital archives of samples which allows for long-term analysis and other predictive analytics. The different types of pathology are human pathology and veterinary pathology. It is used by pharmaceutical and biotechnology companies, hospitals and reference laboratories, and academic and research institutes for drug discovery, disease diagnosis, teleconsultation, and training and education. The digital pathology market covered in this report is segmented – 1) By Product: Scanners, Software, Storage And Communication Systems 2) By Type: Human Pathology, Veterinary Pathology 3) By End-User: Pharmaceutical And Biotechnology Companies, Hospitals And Reference Laboratories, Academic And Research Institutes 4) By Application: Drug Discovery, Disease Diagnosis, Teleconsultation, Training And Education The digital pathology market size has grown rapidly in recent years. It will grow from $1.07 billion in 2023 to $1.26 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to rapid growth in the elderly population, increase in medical errors, increase in cancer prevalence, increase in chronic diseases, growth in the number of healthcare facilities, increased healthcare expenditure, public health insurance reforms, and the COVID-19 pandemic. The digital pathology market size is expected to see rapid growth in the next few years. It will grow to $2.41 billion in 2028 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to government support, increasing adoption of digital devices, increasing prevalence of cancer and chronic diseases, aging population, and the emergence of infectious diseases. Major trends in the forecast period include leveraging artificial intelligence to improve automation, focusing on cloud technology to standardize and simplify digital pathology deployments, adopting digital imaging and video streaming technology, focusing on developing new technological solutions, focusing on partnerships to expand product portfolio and investing in research and development (R&D) activities.

Digital Pathology Market Surges As Prevalence Of Cancer Drives Demand For Advanced Diagnostics

The increased prevalence of cancer contributed to the growth of the digital pathology market. Digital pathology allows patients to accelerate the diagnosis and treatment of cancer, and thus an increase in cancer cases is driving the growth of the market. according to the 2021 American Cancer Society report, 1.8 million new cases of cancer diagnosed were diagnosed in 2020. There is a rise in the number of cancer cases due to the growing elderly population globally coupled with unhealthy lifestyles. Increasing incidences of cancer increases the demand for digital pathology as it makes it easier to access the image faster, view all relevant information, and help diagnose faster.

Digital Pathology Market Thrives On The Frontline Of Emerging Infectious Diseases

The digital pathology market is expected to be supported by the emergence of infectious diseases and other novel pathogenic infestations. Diseases such as SARS, Zika virus, Ebola, and COVID-19 have increasingly led to infections in various parts of the world, leading to an increase in the global disease burden. Digital pathology allows pathologists, laboratorians, and other medical and veterinary professionals to receive real-time consultation for pathologic diagnosis of suspected cases of infectious diseases. It is estimated that zoonotic infectious agents (infectious diseases of animals that evolve to infect human hosts) constitute about 60% of the known human pathogens and up to 75% of emerging human pathogens. Climate change is expected to bring major changes to the epidemiology of infectious diseases through changes in microbial and vector geographic ranges. Microbes can adapt to higher temperatures, and thus there is a growing concern that global warming will select for microbes with higher heat tolerance that can defeat human endothermy defenses, bringing new infectious diseases and changing the epidemiology of many existing diseases, thus driving the demand for digital pathology and supporting the growth of the market. Major companies operating in the digital pathology market report are Danaher Corporation, Hoffmann-La Roche Ltd., Koninklijke Philips N.V, Hamamatsu Photonics K.K, 3DHISTECH Ltd., Olympus Corporation, Nikon Corporation, Visiopharm A/S, Indica Labs Inc., Sectra AB, Grundium, Leica Biosystems, Apollo Enterprise Imaging Corp, Inspirata Inc., PathAI, Aiforia Technologies, Proscia, Ibex Medical Analytics, Better Doc, Biovotion, BrainControl, Coimbra Genomics, Dacadoo, Doctoralia, Emperra, Exovite, Genexyx, Giraff, Healthbank, NeurNation, Nutrino, Psious, Px Healthcare, SilverCloud, Systems Healthcare Solutions, TrialReach, XtremeVRI, Ventana Medical Systems, Huron Digital Pathology, Synevo, Gero AI, TeleMD, mediSensum, Apteki +, ECG for Everybody, Paige.ai, Morphle, Akoya, Aperio Digital Pathology, Smart in Media, MaRS, Perkin Elmer, Definiens AG, Digipath, Nuclei, Aspen Medical, Ensign Medical Coding, Al Talouk Medical Coding Training, WCM-Q, Response Plus Holding, Health-Tech Training, CAE, Medical-X, C3? Holter Monitor, BIOEGYPT, Pulse

Impeding Digital Pathology Market Growth In Regions Struggling With Healthcare Resources

The lack of trained pathologists acted as a restraint for the digital pathology market in the historic period. Pathologists are critical in performing laboratory tests essential for disease diagnosis as pathologists need to examine samples and interpret medical laboratory tests for patients to receive proper treatment. There is a dearth of pathologists in the Asia-Pacific region and countries in Africa. For instance, in February 2022, according to a forensic magazine report, 217 bodies were waiting to be examined by the state's forensic pathologists, and the figure might rise to 300 in less than two weeks. Moreover, more than 200 bodies were waiting for autopsies.

Rising Adoption Of Artificial Intelligence (AI) Enhances Automation And Precision In Digital Pathology

Artificial intelligence (AI) is a key trend gaining popularity in the digital pathology market. AI has been used by healthcare companies to improve the automation of several operational operations. Image classification is also used by AI algorithms to detect features of human diseases like cancer cells, as well as crop diseases like leaf coloring and decay. For instance, in January 2022, Inform Diagnostics, a US-based pathology lab, launched the Paige FullFocus digital pathology viewer in its laboratories. Adoption of the new technology allows pathologists at Inform Diagnostics to use AI tools, streamline logistics, and achieve faster turnaround times for results.

SourceBio International Plc Strengthens Position In Digital Pathology With Acquisition Of LDpath Ltd

In March 2022, SourceBio International PLC, a UK-based provider of integrated laboratory services and products, acquired LDPath Ltd., for an initial £18.5 million ($19.76 million) and is planning a share buyback, as it makes use of the cash generated from its Covid PCR testing services over the past two years. The acquisition strengthens its position to become the leading outsourced partner providing cellular pathology testing to NHS trusts and private healthcare providers in the UK, with the enlarged group targeting the conversion of both NHS and private clients to the digital pathology offering. LDPath is a UK-based provider of digital pathology testing services. North America was the largest region in the digital pathology market in 2023. Asia-Pacific was the second-largest region in the digital pathology market. The regions covered in the digital pathology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital pathology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The digital pathology market consists of the sales of slide scanners, software, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The digital pathology market research report is one of a series of new reports from The Business Research Company that provides digital pathology market statistics, including digital pathology industry global market size, regional shares, competitors with a digital pathology market share, detailed digital pathology market segments, market trends and opportunities, and any further data you may need to thrive in the digital pathology industry. This digital pathology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilar Hormones Market Definition And Segments

Biosimilar hormones refer to the hormones included in the product that are chemically identical to those produced by your body. The hormones in bioidentical drugs may be identical to those used in conventional hormone therapy. They are used to treat people whose hormone levels are low or out of whack. The main types of biosimilar hormones are teriparatidebiosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars and others. Teriparatide is a parathyroid hormone recombinant (PTH). Teriparatide is similar to a component of human PTH, and when taken regularly, it stimulates osteoblasts more than osteoclasts, increasing bone mass. The different applications include research and biotechnology, diagnostics, biocatalysts, therapeutics, and others, and are distributed through various channels such as hospital and retail pharmacies, online pharmacies or e-pharmacy, and specialty clinics. The biosimilar hormones market covered in this report is segmented – 1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types 2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications 3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics The biosimilar hormones market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $4.98 billion in 2024 at a compound annual growth rate (CAGR) of 27.5%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, increasing aging population, growing awareness of biosimilar hormones, and expanded access to healthcare. The biosimilar hormones market size is expected to see exponentially grown in the next few years. It will grow to $11.77 billion in 2028 at a compound annual growth rate (CAGR) of 24.0%. The growth in the forecast period can be attributed to expanding hormone targets, growing patient acceptance, advances in manufacturing, government support, growing clinical trial data, and expanded access to healthcare. Major trends in the forecast period include personalized hormone replacement, product launches, pricing and access, and patient-centric care.

Rising Demand For Hormone Biosimilars Fueled By Prevalence Of Hormonal Deficiencies

The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions have evolved over the years, and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilar market. For instance, in January 2022, according to the British Medical Journal, a UK-based peer-reviewed medical trade journal, the prevalence of GH deficiency (GHD) in children is thought to range from 1 in 3500 to 1 in 10000 across the globe. Also, in June 2022, according to a Medscape report, about 6,000 adults are expected to be diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the growth of the biosimilar hormones market.

Rising Diabetes Epidemic Fuels Growth In Biosimilar Hormones Market

The increased prevalence of diabetes is expected to propel the growth of the biosimilar hormones market. Diabetes is a persistent health condition that impacts the body's ability to convert food into energy. Biosimilar hormones, including insulin, offer safe and efficient alternatives for managing diabetes, potentially resulting in reduced expenses and improved accessibility for patients. Biosimilar growth hormone can help in the treatment of diabetes by improving blood sugar control in adults with type 1 and type 2 diabetes. For instance, in July 2021, the International Diabetes Federation (IDF), a Germany-based umbrella organization of over 240 national diabetes associations, stated in its IDF Diabetes Atlas 10th edition that the estimated global population of individuals living with diabetes is expected to increase to 643 million by 2030 and further to 783 million by 2045, up from approximately 537 million adults aged 20 to 79 living with diabetes in the year 2021. Therefore, the increased prevalence of diabetes will be driving the growth of the biosimilar hormones market going forward in the future. Major companies operating in the biosimilar hormones market include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd., Merck & Co., Biogen Inc., Boehringer Ingelheim, Coherus BioSciences Inc., Alvotech, BioXpress Therapeutics, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

Regulatory Hurdles Impeding Growth In The Biosimilar Hormones Market

Stringent regulations imposed on the approval of hormone biosimilars limit the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market.

Leading Biosimilar Hormones Manufacturers Forge Partnerships And Launch In Untapped Markets

Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launches in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products in various locations to boost sales and maximize profits. For instance, in February 2022, Alvotech Holdings S.A., a Luxembourg-based biopharmaceutical company specializing in the development of biosimilar medicines, announced partnerships with Fuji Pharma Co. Ltd., a Japan-based pharmaceutical company, to develop biosimilar drug candidates in Japan. Through this partnership, both companies have decided to add new elements to their strategic alliance for the creation and marketing of biosimilar medicines in Japan.

Novo Nordisk's Sogroya Injection Receives FDA Approval For Pediatric Use

Major companies operating in the biosimilar hormones market are innovating new products, such as Sogroya (somapacitan-beco) injection, to increase their profitability in the market. Sogroya (somapacitan-beco) is a prescribed analog of human growth hormone (GH) utilized to treat individuals diagnosed with growth hormone deficiency (GHD). For instance, in April 2023, Novo Nordisk, a Denmark-based pharmaceutical company, got the FDA approval for a new indication for Sogroya (somapacitan-beco) injection for the treatment of children aged 2.5 years and older who have growth failure because of insufficient endogenous growth hormone secretion. Sogroya stands as the sole once-weekly growth hormone (GH) therapy designed for both children and adults. The approval was grounded on findings from the phase 3 REAL4 trial, demonstrating the effectiveness of Sogroya in addressing growth hormone deficiency (GHD) in pediatric patients. North America was the largest region in the biosimilar hormones market in 2023. The regions covered in the biosimilar hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The biosimilar hormones market consists of sales of estrace, estradil, and estring. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biosimilar hormones market research report is one of a series of new reports from The Business Research Company that provides biosimilar hormones market statistics, including biosimilar hormones industry global market size, regional shares, competitors with a biosimilar hormones market share, detailed biosimilar hormones market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar hormones industry. The biosimilar hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Laboratory Automation Systems Market Definition And Segments

Laboratory automation systems refer to the use of instruments to carry out laboratory tasks with a minimum of human involvement. Clinical laboratories operate more efficiently because of laboratory automation, which helps to standardize tests. The main equipment and software of laboratory automation systems are automated liquid handling, microplate readers, standalone robots, and automated storage and retrieval. The microplate reader is an instrument that is used to measure biological, chemical or physical reactions of analytes within the wells of the microplate. The various types include modular automation, total lab automation that is used in applications such as drug discovery, clinical diagnostics, genomics solutions, proteomics solutions, and other applications. The end users covered in this market are biotechnology and pharmaceutical industries, research institutes, hospitals, private labs, and academic institutes. The laboratory automation systems market covered in this report is segmented – 1) By Type: Modular Automation, Total Lab Automation 2) By Equipment And Software: Automated Liquid Handling, Microplate Readers, Standalone Robots, Automated Storage, Retrieval 3) By Application: Drug Discovery, Clinical Diagnostics, Genomics Solutions, Proteomics Solutions, Others 4) By End User: Biotechnology And Pharmaceutical Industries, Research Institutes, Hospitals And Private Labs, Academic Institutes The laboratory automation systems market size has grown strongly in recent years. It will grow from $5.28 billion in 2023 to $5.57 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increase in medical errors, growth in the number of healthcare facilities, economic growth in emerging markets, a rise in healthcare expenditure and rapid growth in the elderly population. The laboratory automation systems market size is expected to see strong growth in the next few years. It will grow to $6.86 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rapid technological advances, rising aging population, increasing prevalence of chronic diseases, COVID-19 and increase in lifestyle diseases will drive the growth. Major trends in the forecast period include emphasizing more on investing in research and development, collaborating with artificial intelligence companies, partnering with other players in the market, coming up with more efficient laboratory automation solutions, incorporating RFID technology, bringing new product launches and approvals and receiving aid from government initiatives.

Revolutionizing Clinical Microbiology Boosts Laboratory Automation Market

Increased demand for microbiology testing and standardization of sample-collection devices for microbiology culture has driven the adoption of automated laboratory systems for culture-based laboratory testing in clinical microbiology. Culture-based microbiology laboratory testing by manual methods is being replaced by automated methods with the help of total laboratory automation. For instance, popular systems such as Becton Dickinson’s Kiestra TLA, Copan’s WASPLab, and others enable total laboratory automation (TLA) for culture-based microbiology testing. The potential to affect laboratory efficiency, turnaround time, and the overall quality of culture-based microbiology testing, is driving the automated laboratory systems market growth.

Laboratory Automation Market Thrives Amid Pharmaceutical And Biotechnology Advancements

Increased growth of the pharmaceutical and biotechnology is expected to propel the growth of the laboratory automation market going forward. The growth of the pharmaceutical and biotechnology industries can be attributed to several key factors such as medical advancements, aging population, emerging diseases, drug innovation, R&D investment, biomanufacturing, etc. Laboratory automation is widely used in the pharmaceutical and biotechnology sectors for various purposes such as sample preparation, liquid handling, cell culture and assay setup, drug formulation, and other applications. For instance, in March 2023, according to the 2022-23 annual report published by The Department Of Pharmaceuticals, the total annual turnover of Indian Pharmaceuticals in the fiscal year of 2021-22 was $ 42.34 billion, at the rate of 4.82% as compared to the previous year. Additionally, in September 2022, according to an article published by The White House, a US-based government portal, the United States announced the Department of Health and Human Services announced $40 million to enhance the role of biomanufacturing in the production of active pharmaceutical ingredients (APIs), antibiotics, and critical starting materials required for essential medication production and pandemic response. Therefore, an increased growth of the pharmaceutical and biotechnology is driving the growth of the laboratory automation market. Major companies operating in the laboratory automation systems market report are Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific, Agilent Technologies, Inc., Tecan Group Ltd., PerkinElmer, Inc., F. Hoffmann-La Roche AG, QIAGEN N.V., Becton Dickinson and Company, Siemens AG, Brooks Automation, Inc., Hamilton Company, Eppendorf Ag, Biotek Instruments, Inc., Bee Robotics Ltd., Gilson Inc., Labware, Artificial, Intersystems, Biomerieux, Cerner Corporation, LTS Health, Omnia Health, Sysmex, Formulatrix, Beckman Coulter, Festo ZA

Shortage Of Skilled And Trained Healthcare Professionals

The laboratory automation systems market growth is limited due to a severe shortage of skilled and trained healthcare professionals for operating the advanced laboratory equipment which requires specialized skillsets. These skillsets are limited to some hospitals, research organizations, and medical equipment companies in the USA and Europe, this is expected to be a major restraint on the market. 40% of the healthcare industry was facing difficulties in hiring process development staff due to a shortage of talent. According to the American Society for Clinical Pathology (ASCP) survey, average job-vacancy rates exceed 50% in some states. This shortage also led to a rise in competition and salaries for the limited talent pool available, thereby further limiting the laboratory automation systems market growth.

Implementation Of Rfid Technology To Enhance Laboratory Automation

The hospital laboratories are increasingly adopting RFID technology for laboratory automation systems due to its better productivity and product quality reduced costs for technology, error reduction, faster delivery of samples, and reduced human intervention. Radio Frequency Identification (RFID) technology is an automatic system of identification based on wireless communication, consisting of a tag and a reader which can communicate through radiofrequency. RFID technology is similar to bar code technology but is more beneficial as it can perform some additional functions and actions automatically without human intervention than bar code technology. An RFID system is equipped with a transponder, transceiver, and a data processing unit to meet enhanced identification and tracking requirements in hospital laboratories. Laboratory automated systems use RFID tags attached with patient samples for identification and smart cards to store patients’ data under a workstation that monitors the process in the laboratory. For instance, Mayo Clinic, a healthcare company, adopted RFID-enabled laboratory automation systems to minimize errors by 70%, maximize efficiency and patient safety, and reduce specimen turnaround time by 50%.

Advanced Robotic Technology To Strengthen Laboratory Automation Capabilities

Major companies in the laboratory automation market is introducing innovative technologies such as Flex Robot to gain a competitive edge in the market. The Flex robot is engineered to provide a technologically advanced yet cost-effective automation platform tailored for life scientists. For instance, in May 2023, Opentrons, a US-based lab automation company launched its latest innovation, the Flex robot, with the goal of expanding the availability of advanced lab automation solutions to life scientists. The robot is programmed to perform a wide range of experiments, including those formulated by large language models (LLMs) like ChatGPT.

SPT Labtech Acquired Biomicrolab

In March 2021, SPT Labtech, a UK-based automated instrumentation manufacturer, acquired BioMicroLab for an undisclosed amount. The acquisition would strategically expand product offerings of SPT Labtech in the fields of life sciences sample management. BioMicroLab is a US-based robotics automation provider for life sciences laboratories. North America was the largest region in the laboratory automation systems market in 2023. Western Europe was the second largest region in the global laboratory automation systems market analysis. The regions covered in the laboratory automation systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the laboratory automation systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain The laboratory automation systems market consists of sales of clinical laboratory machines, equipment, and instruments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The laboratory automation systems market research report is one of a series of new reports from The Business Research Company that provides laboratory automation systems market statistics, including laboratory automation systems industry global market size, regional shares, competitors with a laboratory automation systems market share, detailed laboratory automation systems market segments, market trends and opportunities, and any further data you may need to thrive in the laboratory automation systems industry. This laboratory automation systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

3D Cell Culture Technologies Market Definition And Segments

Cell culture is a process for developing substrates for the safe production of viral vaccines. 3D cell culture is an in vitro technique wherein the cells can grow in an artificially created environment. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The 3D cell culture technologies market covered in this report is segmented – 1) By Type: Scaffold-based, Scaffold-free, 3D Bioreactors 2) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine 3) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users Subsegment: Hydrogels, Polymeric scaffolds, Micropatterned Surface Microplates, Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting The 3D cell culture technologies market size has grown rapidly in recent years. It will grow from $2.85 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 19.0%. The growth in the historic period can be attributed to advancements in cell biology, drug development, rising incidence of chronic diseases, government funding. The 3D cell culture technologies market size is expected to see rapid growth in the next few years. It will grow to $6.94 billion in 2028 at a compound annual growth rate (CAGR) of 19.6%. The growth in the forecast period can be attributed to pharmaceutical industry, increasing research and development, environmental and ethical considerations. Major trends in the forecast period include personalized medicine, technological advancements, bioprinting, regenerative medicine.

Increased Demand For Organ Transplantation Boosts The 3D Cell Culture Technologies Market

The increasing requirement for organ transplantation is driving the 3D cell culture technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. For instance, in January 2023, according to United Network for Organ Sharing (UNOS), a US-based non-profit organization, In 2022, 42,887 organ transplants were performed in the United States, an increase of 3.7% over 2021. A total of 14,903 people became deceased organ donors nationwide in 2022, representing the twelfth consecutive record year for deceased donations and an increase of 7.5% over 2021. As the medical criteria for deceased organ donation continue to broaden based on favorable clinical experience, increasing proportions of donors come from less traditional categories of eligibility. In 2022, 4,776 people donated after circulatory death (DCD donors) as opposed to brain death, representing an increase of nearly 14% over the 2021 total. There were 5,789 deceased donors aged 50 or older, the first time there have been more than 5,000 donors of that age range in a single year.

Surge In Drug Discovery For 3D Cell Culture

The surge in drug discovery is expected to propel the growth of the 3D cell culture technologies market going forward. Drug discovery refers to discovering potential new medicinal entities by combining computational, experimental, translational, and clinical models. 3D cell culture technologies are playing an increasingly important role in drug discovery by providing more accurate and reliable results, allowing for microscale 3D cultures, providing higher predictive value for clinical outcome, and avoiding the use of animal models. For Instance, in January 2023, according to Food and Drug Administration, a US-based federal agency of the Department of Health and human services, 37 new drugs and therapeutic biological products were approved by FDA’s Centre for Drug Evaluation and Research (CDER) in the US, in 2022 for various indications. Therefore, the surge in drug discovery is driving the growth of the 3D cell culture technologies market. Major companies operating in the 3D cell culture technologies market include Becton Dickinson and Company, Corning Incorporated, Eppendorf AG, GE Healthcare a division of General Electric Company, Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, HiMedia Laboratories Pvt. Ltd., Agilent Technologies Inc., PromoCell GmbH, CellGenix GmbH, Greiner Bio-One International GmbH, Irvine Scientific Sales Company Inc., Cell Culture Company LLC, SeraCare Life Sciences Inc., American Type Culture Collection (ATCC), Miltenyi Biotec B.V. & Co. KG, AITbiotech Pte Ltd., Essen BioScience a Sartorius Company, Sigma-Aldrich, Bel-Art Products Inc., MilliporeSigma, Sumitomo Bakelite, EMD Millipore, Affymetrix Inc., VWR International LLC., WHEATON Industries., Sartorius AG, CN Bio Innovations, Nortis Inc., Kiyatec, Nanofiber Solutions, Copner Biotech, Known Medicine, Synthecon Inc., 3D Biotek LLC, 3D Cell Culture Innovations LLC., 3D Matrix Inc., Allevi Inc., BioSpherix Ltd., Emulate Inc., MicroTissues Inc.

Challenges Of Cell Contamination Impacting The 3D Cell Culture Technologies Market

The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures.

Embracing Advanced Technology Within Vitro/Vivo Environments In The 3D Cell Culture Market

Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement in the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek'sPolycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA-approved implants and drug delivery devices.

Peptigels And Pods Synergy Transforms Cell Culture

Major companies operating in the 3D Cell Culture Technologies market are introducing innovative products, such as PODS-PeptiGels, to gain a competitive edge in the market. PODS-PeptiGels combines two innovative cell culture technologies—synthetic peptide hydrogels (PeptiGels) and a range of sustained-release growth factors (PODS)—to provide a reproducible and highly adaptable environment for 3D cell culture. For instance, in April 2022, according to Cell Guidance Systems, a UK-based biotechnology company collaborated with Manchester BIOGEL to launch PODS-PeptiGels for 3D cell culture. The ready-to-use kit allows researchers to mix and match to suit the aims of their research by selecting from more than 70 growth factors and combining them with hundreds of combinations of hydrogels, each with mechanical and biomimetic tuneability. Manchester Biogel is a UK-based biotechnology company specializing in the design and manufacture of 3D synthetic peptide hydrogels.

CELLINK Enters Contract Research Market With Acquisition Of Visikol Corporation

In May 2021, CELLINK Group, a USA-based start-up that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. North America was the largest region in the 3D cell culture technologies market in 2023. Western Europe was the second largest region in the 3D cell culture technologies market. The regions covered in the 3d cell culture technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada The 3D cell culture technologies market consists of sales of 3D cell culture technologies such as microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The 3D cell culture technologies market research report is one of a series of new reports from The Business Research Company that provides 3D cell culture technologies market statistics, including 3D cell culture technologies industry global market size, regional shares, competitors with a 3D cell culture technologies market share, detailed 3D cell culture technologies market segments, market trends and opportunities, and any further data you may need to thrive in the 3D cell culture technologies industry. This 3D cell culture technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Specialty Enzymes Market Definition And Segments

Specialty enzymes refer to proteins that can operate as very selective biocatalysts to speed up reactions and create the required target molecule in medicines. Specialty enzymes are important in a wide range of treatment modalities and applications, most frequently for modification but also to lower viscosity and hence enhance processability and to connect and detach cells, which increases productivity. The main types of specialty enzymes market are carbohydrates, proteases, lipases, polymerases & nucleases, oxidases and hydratases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include microorganisms, animals, and plants and are used in pharmaceuticals, diagnostics, research and biotechnology, food and beverage, animal nutrition, and others. The specialty enzymes market covered in this report is segmented – 1) By Type: Carbohydrases, Proteases, Lipases, Polymerases & Nucleases, Oxidase & Hydratases, Other Types 2) By Source: Microorganisms, Animals, Plants 3) By Application: Pharmaceutical, Diagnostics, Research & Biotechnology, Food & Beverage, Animal Nutrition, Other Applications The specialty enzymes market size has grown strongly in recent years. It will grow from $6.39 billion in 2023 to $6.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to prevalence of chronic diseases, growing demand for biofuels and bio-based products, expanding food and beverage industry, rising demand for sustainable and environmentally friendly products. The specialty enzymes market size is expected to see strongly grown in the next few years. It will grow to $8.84 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to biopharmaceuticals growth, renewable energy focus, agricultural and crop sciences, research and development on specialty enzymes, increasing consumer focus on health and wellness, pharmaceutical and healthcare expansion. Major trends in the forecast period include customized enzymes, microbial sourcing, enzyme engineering, digitalization and automation, green chemistry, microbial sourcing.

Biotechnology Research Investment Driving Specialty Enzymes Market Growth

Growing investment in biotechnology research and development is expected to boost market growth during the forecast period. Specialty enzymes are widely used in biotech research and development, particularly in molecular biology. The increasing investment and an increase in the number of companies conducting biotechnology research and development will in turn increase the number of biotech researchers. For instance, in April 2021, according to a report published by the Congressional Budget Office, a US-based government agency that provides budget and economic information, pharmaceutical companies will have invested $83 billion in research and development activities around the world. As a result of increased investment in biotech research and development, the growing number of biotech research companies is expected to boost the specialty enzymes market.

The Growing Demand From The Food And Beverage Industry Fuels Specialty Enzymes Market Growth

The increasing demand from the food and beverage industry is expected to boost the growth of the specialty enzymes market going forward. The food and beverage industry encompasses businesses involved in the production, distribution, and sale of edible goods and drinks, ranging from agriculture and manufacturing to restaurants and cafes. Specialty enzymes play a crucial role in the food and beverage industry by enhancing flavor profiles, improving texture, and facilitating complex biochemical reactions during processing. For instance, in 2023, according to the Food and Drink Federation, a UK-based organization representing and advising UK food and drink manufacturers, the exports of food and drink experienced a substantial 31% increase in 2022 compared to 2021. Further, the food and beverage industry boasted a remarkable turnover of $10.84 billion (£10.3 billion) in 2022, contributing to 33% of the total manufacturing output in Scotland. Therefore, the increasing demand from the food and beverage industry is driving the growth of the specialty enzymes market. Major companies operating in the specialty enzymes market include BASF SE, Novozymes A/S, Roche Holding AG, Codexis Inc., Specialty Enzymes & Probiotics, Advanced Enzyme Technologies Ltd., BBI Solutions, E. I. du Pont de Nemours and Company, Sanofi, Amano Enzyme Inc., Nagase & Co. Ltd., Affymetrix Inc., Biocatalysts Ltd., Life Technologies Corporation, Amicogen Inc., AB Enzymes, Dyadic International Inc., Chr. Hansen Holding A/S, Merck KGaA, Biovet Private Limited., Antozyme Biotech, Kerry Inc., Thermo Fisher Scientific Inc., Koninklijke DSM N.V., Aum Enzymes, Ultra Bio-Logics Inc., Aumgene Biosciences, The Soufflet Group, Shandong Longda Bio-Products Co. Ltd., Enzyme Development Corporation, International Flavors and Fragrances Inc., Enzyme Supplies Ltd., Alphazyme LLC, Enzyme Innovation inc., Creative Enzymes, Enzyme Solutions Inc., EnzymeWorks Inc., Enzyme Technologies Corporation, Enzyme Research Labs Inc., Enzyme Systems Products, Enzyme Bioscience Pvt. Ltd.

Challenges Arising From Ethical And Societal Concerns In The Market.

Ethical and societal issues are factors that will slow down the market's growth during the forecast period. The clashing public opinions on these issues will determine the acceptability of new industrial biotechnology products. For instance, in 2023, according to the European Chemical Bulletin (ECB), a peer-reviewed journal, the ethical, legal, and social implications (ELSI) framework often calls for more stringent regulations to ensure the ethical, legal, and social considerations are adequately addressed. While necessary, these regulations can create additional burdens for biotech companies, increasing compliance costs and potentially stifling innovation. Failures to address ELSI issues can manifest as significant roadblocks to the acceptance and adoption of biotechnology products. Thus, societal and ethical issues are expected to impact market growth.

Technological Advances In Enzyme Products

Technological advancements show opportunities for the production of enzyme products more efficiently. Challenges such as complexity in maintaining pH, the operational high temperature of specialty enzymes, and the significant cost of maintenance of specialty enzyme products pave the way for technological advancements. For instance, in March 2021, International Flavors and Fragrances Inc., a US-based company that produces flavors, fragrances, and cosmetic actives, announced the launch of Enovera 3001, an enzyme-only solution. Enovera 3001 is a dough strengthener that has been shown to replace vital wheat gluten, especially in challenging applications such as whole wheat bread. The enzyme technology in Enovera 3001 performs equivalently or better than traditional emulsifiers and with reduced dependence on aids used to compensate for inconsistencies.

Trend- Increasing Focus On Introducing Non-GMO Enzyme To Gain A Competitive Edge

Major companies operating in the specialty enzymes market are focused on developing innovative enzymes such as non-GMO enzymes to gain a competitive edge in the market. Non-GMO specialty enzymes are employed to catalyze specific reactions in biotechnological processes without genetic modification. For instance, in March 2021, Amano Enzyme Inc., a Japan-based enzyme product manufacturer, announced the launch of Umamizyme Pulse, a non-GMO enzyme designed to enhance the savory taste of plant-based proteins and improve the flavor of meat substitutes. The enzyme is suitable for use in various plant protein products, offering a pleasant and umami-rich experience.

Brain Ag Strengthens BioIndustrial Segment With Acquisition Of Biocatalysts Ltd. Shares

In May 2021, BRAIN AG, a Germany-based industrial biotechnology company that identifies and develops innovative solutions and products for use in the chemistry, cosmetics, and food industries, paid $ 5.51 million (GBP 3.9 million) for additional shares in Biocatalysts Ltd. The acquisition further strengthens BRAIN’s BioIndustrial segment and widens commercial opportunities with Biocatalyst's portfolio and technology, including access to BRAIN’s unique BioArchive and Biocatalyst’s MetXtra metagenomic library. Biocatalysts Ltd. is a UK-based manufacturer of specialty enzymes that focuses on the use of technology to develop novel specialty enzymes cost-effectively. North America was the largest region in the viral specialty enzymes market in 2023. Middle East is expected to be the fastest growing region in the specialty enzymes market report during the forecast period. The regions covered in the specialty enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the specialty enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The specialty enzymes market consists of sales of acylases, hydratases, humulin oxidase, and lyases. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The specialty enzymes market research report is one of a series of new reports from The Business Research Company that provides specialty enzymes market statistics, including specialty enzymes industry global market size, regional shares, competitors with a specialty enzymes market share, detailed specialty enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the specialty enzymes industry. This specialty enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Scientific Research And Development Services Market Definition And Segments

The scientific research and development services are responsible for conducting original research on a systematic basis to gain new knowledge and to apply research findings or other scientific knowledge to create new or improved products or processes. The main types of scientific research and development services are social sciences and humanities services, physical, engineering, and life sciences, nanotechnology services, and biotechnology services. Nanotechnology is the near-atomic manipulation of matter to create new structures, materials, and technologies. Many fields, including medical, consumer goods, energy, materials, and manufacturing, will benefit from the technology. The different sizes of enterprises include large enterprises, small and medium enterprises, and involve various modes such as online and offline. The scientific research and development services market covered in this report is segmented – 1) By Type: Social Sciences And Humanities Services, Physical, Engineering, And Life Sciences, Nanotechnology Services, Biotechnology Services 2) By Mode: Online, Offline 3) By End User Size: Large Enterprise, Small and Medium Enterprise The scientific research and development services market size has grown strongly in recent years. It will grow from $842.79 billion in 2023 to $906.01 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to corporate R&D investments, government funding for research, environmental research, defense and aerospace research, globalization of research. The scientific research and development services market size is expected to see strong growth in the next few years. It will grow to $1,256.12 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to renewable energy research, space exploration, pandemic preparedness, human genetics research, smart cities research, remote sensing and earth observation. Major trends in the forecast period include artificial intelligence (AI) in research, global collaboration in research projects, innovation in materials science and nanotechnology, integration of data science in research methodologies, robotics and automation research.

Role Of Scientific Research And Development Services In Addressing The Global Surge In Chronic Diseases

The rising prevalence of chronic diseases is expected to propel the growth of the scientific research and development services market going forward. Chronic diseases refer to a wide range of chronic conditions that are long-lasting and typically develop over an extended period of time. Scientific research and development services are dedicated to advancing medical science through activities such as conducting clinical trials, testing innovative drugs and therapies, and creating cutting-edge medical devices to address chronic diseases. For instance, in September 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is driving the growth of the scientific research and development services market.

Increasing Demand For New Product Development Drives Growth In The Scientific Research And Development Services Market

Increasing demand for new products is expected to propel the growth of the scientific research and development services market going forward. New products refer to goods or services that are newly developed or improved and introduced to the market. Scientific research and development services play a critical role in developing new products by conceptualizing, designing, and developing new products, exploring new technologies and materials, gaining a competitive edge, ensuring compliance, and conducting market research. For instance, in 2021, the Food and Drug Administration, a US-based federal agency, approved 14 biologics, while in 2022, the number of biologics approved increased to 15. Thus, increasing demand for new products is driving the growth of the scientific research and development services market. Major companies operating in the scientific research and development services market report are Amazon.com Inc., Apple Inc., Volkswagen AG, Alphabet Inc., Toyota Motor Corporation, Samsung Electronics Co. Ltd., Microsoft Corporation, Ford Motor Company, General Motors Company, Honda Motor Co. Ltd., Pfizer Inc., Johnson & Johnson, Siemens AG, Roche Holding AG, Intel Corporation, IBM Corporation, Merck & Co. Inc., Cisco Systems Inc., Novartis International AG, Bristol-Myers Squibb Company, Qualcomm Incorporated, Defense Advanced Research Projects Agency (DARPA), IQVIA Holdings Inc., Battelle Memorial Institute, Piramal Group and WuXi AppTec Co. Ltd., Charles River Laboratories Inc., Frog Design, Lawrence Livermore National Laboratory LLC, Lawrence Berkeley National Laboratory, Jackson Laboratory, Sanofi S.A., GlaxoSmithKline plc

Navigating The Impact Of COVID-19 On The Scientific Research And Development Services Market

The outbreak of COVID-19 disease (COVID-19) has acted as a restraint on the scientific research and development services market in 2020 as governments globally imposed lockdowns and restricted trade, thereby limiting the need for professional services. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of lock down. The outbreak has had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the scientific research and development services market will recover from the shock over the forecast period as it is a black swan event and not related to ongoing or fundamental weaknesses in the market or the global economy.

Strategic Collaborations Drive Innovation In Scientific Research And Development Services Market For Drug Discovery

Major companies operating in the scientific research and development services market are developing strategic partnerships to shape the future of drug discovery and development. Collaboration and partnerships are essential in the Scientific Research And Development Services market, as it helps to drive innovation, speed up drug development, and lead to new discoveries and innovations. For instance, in August 2022, Sanofi, a France-based pharmaceutical company signed a strategic multi-target research collaboration with Atomwise for AI-powered drug discovery. Atomwise's AI technology will be used to identify small molecules that could be used as potential drug candidates. The technology will also be used to predict the efficacy and safety of these drug candidates. Atomwise is a US-based technology-enabled pharmaceutical company.

Evolution Of 3D Printing With Dynamic And Adaptive Capabilities For Diverse Applications, Including Biomedical Advancements

4D printing has evolved from 3D printing with the additional feature of changing the geometrical shape and mechanical properties, with time being integrated as an additional fourth dimension. One of the major drawbacks of 3D printing is that it can only take the shape in which it was originally made and is static and inanimate. With the latest development of 4D printing, objects can now be made with responsive materials with certain inherent properties that can change or transform in response to external stimuli. It has widespread applications in medical science, such as tissue regeneration in the biomedical field. For example, printed micro tissue from bio ink can undergo maturation via cellular coating to form functional tissue constructs such as engineered tissue constructs. Major biotechnology research companies using 4D bio printing technology include Poietis, Biolife4D, and Precise Bio. North America was the largest region in the scientific research and development services market in 2023. Asia-Pacific was the second largest region in the scientific research and development services market. The regions covered in the scientific research and development services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scientific research and development services market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa. The scientific research and development services market consists of revenue earned by entities that engage in research and experimental development on a contract, consultancy, or outsourced basis. Scientific research and development services establishments undertake processes where human capital is the major input. They make available the knowledge and skills of their employees, often on an assignment basis, where an individual or team is responsible for the delivery of services to the client. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The scientific research and development services market research report is one of a series of new reports from The Business Research Company that provides scientific research and development services market statistics, including scientific research and development services industry global market size, regional shares, competitors with a scientific research and development services market share, detailed scientific research and development services market segments, market trends and opportunities, and any further data you may need to thrive in the scientific research and development services industry. This scientific research and development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biotechnology Services Market Definition And Segments

Biotechnology services refer to the services that modify living microorganisms to provide biotechnology products on a contract or custom basis to medical, pharmaceutical, and scientific laboratories. They provide breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner, and more efficient industrial manufacturing processes. The main types of biotechnology services are prevention and disease control, public engagement activities, health education and research, food biotechnology services, donor recruitment, tissue collection, cell processing and isolation, and research and development. Food biotechnology services encompass a diverse variety of technologies used in crops, livestock, forestry, fisheries and aquaculture, and agro-industry. They are used for a variety of purposes, including genetic improvement of plants and animals to increase yields or efficiency, characterization and conservation of genetic resources for food and agriculture, plant and animal disease diagnosis, vaccine development, and fermented food production. The various applications include pharmaceutical, biotechnological, academic, clinical trial, and healthcare sectors and are used by Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research and Manufacturing Services (CRAMS). The biotechnology services market covered in this report is segmented – 1) By Service: Prevention And Disease Control, Public Engagement Activities, Health Education And Research, Food Biotechnology Services, Donor Recruitment, Tissue Collection, Cell Processing And Isolation, Research And Development 2) By Industry: Clinical Research Organizations (CROS), Contract Manufacturers Organizations (CMOS), And Contract Research And Manufacturing Services (CRAMS) 3) By Area Of Application: Pharmaceutical, Biotechnology, Academic, Clinical Trial, Healthcare Sectors, Others The biotechnology services market size has grown strongly in recent years. It will grow from $126.58 billion in 2023 to $133.74 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to strong economic growth in emerging markets, increased collaborations with other research institutes and companies, and increased demand for food. The biotechnology services market size is expected to see strong growth in the next few years. It will grow to $163.12 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to the rapid advancements in technology, rising non-communicable diseases, emphasis on innovation, rising demand for agriculture-based biotechnology services, growing demand for synthetic biology, developments and improvements in drug research, growth in personalized treatment, and collaboration and partnership. Major trends in the forecast period include strategic collaborations, integrating data management systems through cloud technology, development of next-generation sequencing technology, adapting digitalizing techniques in conducting clinical trials, implementing automated solutions, deploying artificial intelligence technologies, and investment in synthetic biology to develop products and solutions.

Effect Of Disease Prevalence And R&D On Biotechnology Services Market

The increasing pervasiveness of conditions like hepatitis B, diabetes, and cancer is driving biotechnology research. Biotechnology uses research tools from biology and chemistry to study the genetic material of bacteria and viruses to check the disease-producing agents. Oncology research is most prominent among biopharma companies. Stem cell treatment using a monoclonal antibody for therapy and genome sequencing is progressing in medical applications. According to the Indian Economic Survey 2021, the Indian biotechnology business is predicted to grow to $150 billion by 2025. Therefore, the rising pervasiveness of diseases and huge expenses on R&D are predicted to contribute to the growth of the biotechnology services market.

Chronic Disease Treatment Driving Biotechnology Services Market

The rising demand for clinical solutions for the treatment of chronic diseases is expected to propel the growth of the biotechnology services market going forward. Chronic diseases refer to long-lasting medical conditions that persist over an extended period, typically for three months or more. Biotechnology services provide innovative clinical solutions for the treatment of chronic diseases by developing advanced therapies, precision medicine, and targeted treatments tailored to individual patients, improving the management and outcomes of chronic conditions. For instance, in September 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, each year there are 41 million deaths worldwide, accounting for 74% of all fatalities attributed to chronic diseases. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the rising demand for clinical solutions for the treatment of chronic diseases is driving the growth of the biotechnology services market. Major companies operating in the biotechnology services market report are Parexel International Corporation, Thermo Fisher Scientific, Laboratory Corporation of America Holdings, IQVIA, ICON PLC, Charles River Laboratories, Syneos Health, Sartorius AG, Precision for Medicine Inc., Novartis, Eppendorf Asia Pacific Sdn. Bhd., Emmessar Biotech & Nutrition Ltd., Vcanbio Cell & Gene Engineering Corp., Ltd., Ke Rui Gene, Absea Biotechnology Ltd., CStone Pharm-B, Daiichi Sankyo, bitBiome, Taisho Pharmaceutical, AGC Biologics, Hamamatsu Pharma Research, Artios Pharma, AstraZeneca, Bio Products Laboratory (BPL), Cambridge Bioscience, Shire Pharmaceuticals Ltd., BTG Ltd., eXmoor Pharma, 4D Pharma PLC, Touchlight Genetics, Ophidia Medical Technologies, ATAI Life Sciences, Phaseform, Evotec, Sanity Group, Primmbiotech, Vaccitech, Biolat, Pharmidea, Asla-Biotech, Genera, Anima Lab, Silvanols, OU TBD-Biodiscovery, Qvalitas Arstikeskus AS, Concise Systems OU, GPE Globalpharma OU, Belarusian National Biotechnology Corporation, Innothera, Olainfarm, Pharmaidea, Amgen Inc., Gilead Sciences, Celgene Corporation, Biogen Inc., Vertex Pharmaceuticals, Illumina, Inc., Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals, Hemostemix Inc., Resverlogix Corporation, Zenith Epigenetics Corp., Bayer, AMEGA Biotech, Pierre Fabre, Pfizer, Quantificare, Apsen Farmaceutica, BioMarin Pharmaceutical, DK Diagnostics, Biosonda Biotechnology, Laboratorios Legrand, Biomerics, Julphar Pharmaceuticals, Medpharma, Pharmax, Neopharma, City Breeze Technical Services, CinnaGen, BioSun Pharmed, AryoGen Pharmed, 4Clinics, 54gene, Amoun, Aspen Pharmacare, BBI Solutions, BioTech Africa, ClinArt MENA, Crux Pharmaceuticals, Genesis Pharmaceuticals, Massive Genomics, Mayne Pharma, Sanofi Genzyme, Teleflex Medical, The Micron Group

Genetic Data Risk Hinders Biotechnology Services Market Growth

The risk related to genetic data is anticipated to limit the growth of the biotechnology services market. The biotechnological approach of transferring specially created genes for modification in characteristics to create genetically modified organisms (GMOs) has always been considered a threat to human and environmental health. According to the report of the World Conservation Union, there are numerous environmental risks likely to occur due to the use of GMOs, which include interbreeding, antibiotic resistance, impact on the ecosystem, creation of new or worse viruses, competition with natural species, unpredictable and unintended effects, and ethical concerns. The World Health Organization (WHO) has also set guidelines for manufacturers of GMO food. In January 2021, The National Bioengineered Food Disclosure Standard was implemented in the USA, making it mandatory to label all foods containing genetically engineered items as ‘bioengineered’. Thus, the risk associated with genetically modified items is negatively impacting the growth of the biotechnology services market.

Collaborations And Partnerships In Biotechnology Services Market

Collaborations and partnerships between industry players are a growing trend in the field of biotech services. In January 2021, Novartis, a Switzerland-based pharmaceutical company collaborated with Alnylam, a US-based biopharmaceutical company, for exploration in the application of the latter’s siRNA technology and the development of targeted therapy for the restoration of liver function. As part of the exclusive three-year research collaboration, Alnylam will develop and test potential siRNAs using Novartis' target-specific assays. Novartis will conduct further development and clinical research once a lead candidate has been identified.

Innovative Therapies In The Biotechnology Services Market

Major companies operating in the biotechnology services market are focusing on developing innovative therapies such as biomarker algorithms for first-line treatment of patients with non-small cell lung cancer (NSCLC). A biomarker algorithm is a mathematical or computational model that combines data from multiple biomarkers or biological indicators to provide a more comprehensive and accurate assessment of a particular biological or medical condition. For instance, in April 2023, Strata Oncology Inc., a US-based precision oncology company, announced the launch of Strata Select, a first-of-its-kind molecular profiling test for patients with advanced cancer. Strata Select is the first immunotherapy biomarker algorithm to be covered by Medicare across solid tumors meeting specified coverage criteria. The launch empowers oncologists to make better-informed treatment decisions and enhance patient outcomes.

Enhancing Amgen's Capabilities Through The Acquisition Of Teneobio

In October 2021, Amgen, a US-based biopharmaceutical company, acquired all outstanding shares of Teneobio for a deal amount of $2.5 billion. Amgen acquired Teneobio's bispecific and multispecific antibody technologies as part of the acquisition. These solutions complement the company's existing antibody expertise and BiTE platform. This will aid in the discovery and advancement of novel molecules for the treatment of a wide range of illnesses in Amgen's major treatment areas. TeneoBio is a US-based biotechnology business that specializes in the production of human heavy chain antibodies. Asia-Pacific was the largest region in the biotechnology services market in 2023. North America was the second largest region in the global biotechnology services market analysis. The regions covered in the biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the biotechnology services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain The biotechnology services market consists of revenue earned by entities that engage in conducting research and experimental development in biotechnology. Numerous global issues are helped by biotechnology, including infectious diseases, ageing societies, food security, energy security, and climate change, to name a few. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biotechnology services market research report is one of a series of new reports from The Business Research Company that provides biotechnology services market statistics, including biotechnology services industry global market size, regional shares, competitors with a biotechnology services market share, detailed biotechnology services market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology services industry. This biotechnology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilar Lymphocyte Modulator Market Definition And Segments

Immune-regulating lymphocyte modulators that produce biosimilars are referred to as biosimilar lymphocyte modulators. Lymphocyte modulator market is intended as an aid in the treatment for cancer and autoimmune diseases, and for regulating carotene intake in humans with a weak immune system. The main types of drugs in biosimilar lymphocyte modulator are Campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar), anti-CD38 daratumumab biosimilar, and anti-CS1 elotuzumab biosimilar. Campath is a prescription medication used to treat the symptoms of CLL. Campath can be taken on its own or in combination with other drugs. The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, and others. By distribution channel, it is segmented into online pharmacies and direct to consumers. The biosimilar lymphocyte modulator market covered in this report is segmented – 1) By Drug: Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar 2) By Disease: Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis, Other Diseases 3) Distribution Channel: Online Pharmacies, direct-to-consumer The biosimilar lymphocyte modulator market size has grown rapidly in recent years. It will grow from $1.71 billion in 2023 to $1.91 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to the rising prevalence of immune-mediated diseases, increasing awareness of lymphocyte modulators, growing government support for biosimilars, and expansion of the biosimilar. The biosimilar lymphocyte modulator market size is expected to see rapidly grown in the next few years. It will grow to $2.86 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing patient demand for biosimilars, growing patient population, growing demand for personalized medicine, growing demand for minimally invasive procedures, and expanding biologic drug portfolio. Major trends in the forecast period include advances in biosimilar technology, quality and efficacy assurance, patient-centric approaches, biosimilars, and biologic innovation.

Immunotherapy Combinations Drive Growth In The Biosimilar Lymphocyte Modulator Market

Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulator market. The combination of immunotherapies or pairing of immunotherapies with other types of cancer treatments, such as chemotherapy or radiation, enhances the benefit associated with lymphocyte modulators. In December 2021, according to a study conducted by researchers at Washington University School of Medicine in St. Louis, pre-activated natural killer cells will have been shown in a limited clinical trial to be helpful for some adolescents and young adults with recurrent AML who have few other therapeutic choices. Combining the therapies helps determine whether alternative chemotherapy can improve the killing of leukemia cells, and researchers have combined memory-like natural killer cells to see if this is possible. The combination approach, therefore, saves patients’ lives from a life-threatening reaction of the immune system, thereby driving the growth of the lymphocyte modulator market.

Rising Incidence Of Autoimmune Diseases Fuels Growth In The Biosimilar Lymphocyte Modulator Market

The rising incidence of autoimmune diseases is expected to propel the growth of the biosimilar lymphocyte modulator market going forward. Autoimmune diseases are a group of disorders in which the immune system mistakenly targets and attacks the body's tissues and organs. Biosimilar lymphocyte modulators help treat autoimmune diseases by modulating the immune system's activity, reducing inflammation, and alleviating symptoms. For instance, in May 2023, according to the Imperial Biomedical Research Centre, a UK-based National Institute for Health and Care Research, autoimmune disorders now affect about one in ten individuals and there are 19 autoimmune diseases studied that affect about 10% of the population where the 13% of women and 7% of men which is higher than previous estimates. Therefore, the rising incidence of autoimmune diseases is driving the growth of the biosimilar lymphocyte modulator market. Major companies operating in the biosimilar lymphocyte modulator market include Pfizer Inc., Biogen Inc., Celltrion Inc., Genentech Inc., Novartis AG, Sandoz International GmbH, Mylan N.V., Fresenius Kabi AG, Biocon Ltd., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Lupin Limited, Stada Arzneimittel AG, Zydus Cadila, Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Alvotech, Coherus BioSciences, Innovent Biologics, Shanghai Henlius Biotech, BioXpress Therapeutics SA, Mabion SA, Polpharma Biologics, Prestige BioPharma, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical Group Co. Ltd., Wockhardt Ltd., Amega Biotech

Shortage Of Raw Materials Hinders Growth Of The Biosimilar Lymphocyte Modulator Market

The shortage of raw materials for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market. Drug shortages are due to several factors, including challenges in acquiring raw materials, manufacturing problems, regulatory issues, business decisions, and numerous disturbances within the supply chain. They adversely affect patient care by causing the replacement of safe and effective therapies with elective medicines, compromising or delaying medical procedures, or causing medication errors. The American Society of Hematology, an association comprising clinical scientists and physicians that provides care to patients in diverse settings, sent a letter to the US Food and Drug Administration highlighting the issue of the shortage of critical hematologic drugs such as etoposide and methotrexate, which have no alternatives. The chemotherapeutic drug etoposide, in particular, is an important component in treatment regimens designed to be curative for life-threatening conditions such as leukemia and lymphomas. Due to the shortage, some patients have received less effective treatment. Thus, the raw material shortages cause delayed and compromised medical treatments and also result in limiting the growth of the market.

Tumor-Infiltrating Lymphocyte Immunotherapy Gains Momentum In Anti-Cancer Treatment

Tumor-infiltrating lymphocyte immunotherapy has been gaining popularity in recent times because of its positive results in anti-cancer treatments. Tumor-infiltrating lymphocytes (TILs) comprise all lymphocytic cell populations that have occupied the tumor tissue. TILs have been depicted in various solid tumors, including breast cancer, and are emerging as a significant biomarker in predicting the efficacy and result of treatment. Due to promising results, many companies have started launching TIL technologies. For instance, in 2021, Lovance Biotherapeutics, a US-based start-up company, and Iovance successfully carried out phase II trials of TIL therapy for solid tumor treatment.

Fresenius Kabi Launches Idacio Biosimilar To Expand Lymphocyte Modulator Market Presence

Major companies in the biosimilar lymphocyte modulator market are developing biosimilar versions of key lymphocyte modulator drugs to gain a competitive edge in the industry. Idacio (adalimumab-aacf) is a tumor necrosis factor (TNF) blocker and a biosimilar to Humira (adalimumab). For instance, in July 2023, Fresenius Kabi AG, a Germany-based healthcare company, launched the citrate-free biosimilar Idacio (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases in the U.S. It is available in the U.S. in a self-administered prefilled syringe and a self-administered pre-filled pen (autoinjector) to support dosing for the approved indications.

Biocon Biologics Acquires Viatris Inc. Biosimilars Business To Strengthening Global Presence

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. The acquisition brings Biocon Biologics closer to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and numerous emerging regions. In numerous emerging market positions, the merger of Viatris' acquired worldwide biosimilars company with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization Viatris Inc. is a US-based pharmaceutical company that develops, licenses, manufactures, markets, and distributes generic and branded medicines. North America was the largest region in the biosimilar lymphocyte modulator market in 2023. Middle East is expected to be the fastest-growing region in the biosimilar lymphocyte modulator market report during the forecast period. The regions covered in the biosimilar lymphocyte modulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biosimilar lymphocyte modulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The biosimilar lymphocyte modulator market consists of sales of roasted coffee, coffee concentrates, coffee extracts, flavorings, and syrups. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biosimilar lymphocyte modulator market research report is one of a series of new reports from The Business Research Company that provides biosimilar lymphocyte modulator market statistics, including biosimilar lymphocyte modulator industry global market size, regional shares, competitors with a biosimilar lymphocyte modulator market share, detailed biosimilar lymphocyte modulator market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar lymphocyte modulator industry. This biosimilar lymphocyte modulator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.